Compare GSK plc (GSK) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hims and Hers Health Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Hims and Hers Health Inc trades at $29.86 (market cap $7.12B). The key difference: GSK plc is far larger — about 14.4× Hims and Hers Health Inc's market cap, and GSK plc pays a 3.57% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| GSK | HIMS | |
|---|---|---|
Market Cap | $102.60B | $7.12B |
Sector | Health | Health |
52-Week High | $61.18 | $62.76 |
52-Week Low | $38.22 | $14.52 |
Enterprise Value | $123.04B | $7.82B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
HIMS stock trades at $29.97, down 5.67% amid mixed Q2 2026 results. Revenue growth remains strong with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a net loss. Technical indicators are neutral to bearish, with support near $29. Recent news highlights an FTC investigation and class-action lawsuits adding uncertainty.
The outlook is cautious. Growth prospects from AI and global expansion are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33 price target, suggesting limited near-term upside amid execution and profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
